Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02332239 · ClinicalTrials.gov registry record · NA
Text-Message-Based Depression Prevention for High-Risk Youth in the ED
A NA study of Depressive Disorder and Violence, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- NA
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT02332239: Completed NA study of Depressive Disorder and Violence, sponsored by Rhode Island Hospital.
NCT02332239 is a NA study of Depressive Disorder and Violence that has completed, run by Rhode Island Hospital. The registered enrollment target is 116 participants, below the 329-participant average among 47 other Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02332239, a NA study of Depressive Disorder and Violence, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iDOVE," a brief emergency department introductory session + longitudinal automated text-message depression prevention program for high-risk teens.
Primary Outcome
Becks Depression Inventory (BDI-2): To analyze changes in past-two-week depressive symptoms in iDOVE participants, relative to an automated health-and-safety brief intervention and text message program. The Beck Depression Inventory (BDI-2) is a 1996 revision of the BDI, developed in response to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, which changed many of the diagnostic criteria for Major Depressive Disorder. Participants were asked to rate how they have been feeling
Conditions Studied
Interventions
- BEHAVIORAL iDOVE Intervention (ED+text)
- BEHAVIORAL Control (EUC)
Study Locations (1)
Rhode Island
- Rhode Island Hospital Emergency Department - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-05 |
| Phase | NA |
What the finished NCT02332239 record still lists
NCT02332239 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 329-participant average among 47 other Depressive Disorder trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which iDOVE Intervention (ED+text) is the first listed.
NCT02332239 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02332239 about?
NCT02332239 is a clinical study titled "Text-Message-Based Depression Prevention for High-Risk Youth in the ED". The purpose of this randomized controlled study is to evaluate acceptability and feasibility, and to gather preliminary data about efficacy, of "iDOVE," a brief emergency department introductory session + longitudinal automated text-message depression prevention program for high-risk teens.
What is the current status of trial NCT02332239?
This trial is currently completed. It is a NA study. The enrollment target is 116 participants. The study started on 2015-02. Estimated completion is 2017-05.
What conditions does trial NCT02332239 study?
This clinical trial studies the following conditions: Depressive Disorder, Violence.
What interventions are being tested in trial NCT02332239?
The interventions under investigation include: iDOVE Intervention (ED+text) (BEHAVIORAL), Control (EUC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02332239?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02332239 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02332239's enrollment target sits among peer trials
116 22nd of 47 higher than 26 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change
RECRUITING · NA
-
Research Evaluating Vagal Excitation AND Anatomical Links
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
-
Enhancing Brain And Mental Health Through Breathing Practice
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia